<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7383122\results\search\testTrace\results.xml">
  <result pre="of the two-way interaction between heart failure medications and the" exact="infection" post="as well as the proposed COVID-19 medications and heart"/>
  <result pre="Initiating specific cardiac or heart failure medications to prevent the" exact="infection" post="or mitigate the disease is also not an evidence-based"/>
  <result pre="In this review, we explore the risks associated with COVID-19" exact="infection" post="in HF patients and address unique aspects related to"/>
  <result pre="management in the acute and chronic settings when complicating the" exact="infection" post="itself. Heart failure patients and the risk of COVID-19"/>
  <result pre="infection itself. Heart failure patients and the risk of COVID-19" exact="infection" post="In addition to older age, chronic comorbidities increase the"/>
  <result pre="older age, chronic comorbidities increase the risk of severe COVID-19" exact="infection" post="as well as its fatality. The overall global mortality"/>
  <result pre="are generally incapable of. Clinical and hemodynamic implications of COVID-19" exact="infection" post="in HF patients Exacerbation of chronic HF Lessons from"/>
  <result pre="preexciting chronic HF. Heart failure as a manifestation of COVID-19" exact="infection" post="in previously healthy individuals New onset of HF was"/>
  <result pre="heart. Severe acute myocarditis can be a manifestation of the" exact="infection" post="resulting in cardiogenic shock, which can then result in"/>
  <result pre="are best assessed through pulmonary artery catheterization, especially if the" exact="diagnosis" post="will change the management. Markers of cardiac injury (CK-MB"/>
  <result pre="3 continents (Asia, North America, Europe) that looked at the" exact="prevalence" post="of preexisting cardiovascular comorbidities, septic shock, ICU admission, cardiac"/>
  <result pre="injury, and case fertility rate [17â€&quot;19, 23â€&quot;32]. Table 1 The" exact="prevalence" post="of preexisting CVD, outcomes, and complications in patients with"/>
  <result pre="reported by Fried et al. as a complication during the" exact="treatment" post="of COVID 19-related respiratory failure by veno-venous extra-corporeal membranous"/>
  <result pre="of a pandemic and thus only perform imaging and laboratory" exact="testing" post="when indicated. Figure 2 summarizes an approach to COVID-19"/>
  <result pre="myocardial injury Heart failure medications in the setting of COVID-19" exact="infection" post="COVID-19 mechanism of cellular entry has implicated an important"/>
  <result pre="the purpose of mitigating the pandemic and recommended to continue" exact="treatment" post="based on standard indications [48]. COVID-19 suggested medications and"/>
  <result pre="adoption as part of institutional protocols to manage the COVID-19" exact="infection" post="[49, 50]. Both chloroquine and hydroxychloroquine block a potassium"/>
  <result pre="treat Ebola virus and not the current doses used for" exact="treatment" post="in this pandemic, careful monitoring is still warranted given"/>
  <result pre="proarrhythmic agents in advanced stages, as well as the high" exact="prevalence" post="of antiarrhythmics and other concomitant medications that can pause"/>
  <result pre="a loop diuretic, frequent electrolyte abnormalities, and the aforementioned high" exact="prevalence" post="of concomitant QTc prolonging medications. Moreover, heart failure patients"/>
  <result pre="Caring for HF patients while minimizing the risk of COVID-19" exact="infection" post="Care pathways and delivery Remote monitoring The Heart Failure"/>
  <result pre="In the era of a pandemic, and with emphasis on" exact="social distancing," post="the importance of self-care for HF patients is more"/>
  <result pre="patients. It is very likely that the perceived risk of" exact="infection" post="in these patients led them to proactively use measures"/>
  <result pre="rates when compared with the general populations [65]. Additionally, COVID-19" exact="infection" post="with myocarditis in a heart transplant recipient can mimic"/>
  <result pre="case series of 28 heart transplant recipients and a confirmed" exact="diagnosis" post="of COVID-19 from New York reported an alarmingly high"/>
  <result pre="them already had cardiac allograft vasculopathy (CAV). The approach to" exact="treatment" post="followed in these patients included reducing immunosuppression in most"/>
  <result pre="brings up the question as to the best strategy of" exact="treatment" post="for this unique population. The International Society for Heart"/>
  <result pre="disease and organ availability. For donors, current ISHLT recommendations support" exact="testing" post="for the novel virus if the test is available."/>
  <result pre="with COVID-19 or utilizing their inflammatory and cardiac biomarkers for" exact="treatment" post="or prognosis. Although cardiac output provided through the assist"/>
  <result pre="J, Fayad ZA, Bagiella E, Zhao S (2020) Association of" exact="treatment" post="dose anticoagulation with in-hospital survival among hospitalized patients with"/>
  <result pre="in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19)" exact="infection" post="in Wuhan, China. JAMA Cardiol 5(7):1â€&quot;6. 10.1001/jamacardio.2020.1624 46.ClinicalTrials.gov. Randomized"/>
  <result pre="Dupont HT, HonorÃ© S (2020) Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID-19: results of an open-label non-randomized clinical trial."/>
 </snippets>
</snippetsTree>
